<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35301424</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1740-634X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title>
          <ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.</ArticleTitle>
        <Pagination>
          <StartPage>1188</StartPage>
          <EndPage>1198</EndPage>
          <MedlinePgn>1188-1198</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-022-01301-9</ELocationID>
        <Abstract>
          <AbstractText>Lysergic acid diethylamide (LSD) is a serotonergic psychedelic compound receiving increasing interest due to putative anxiolytic and antidepressant properties. However, the potential neurobiological mechanisms mediating these effects remain elusive. Employing in vivo electrophysiology, microionthophoresis, behavioral paradigms and morphology assays, we assessed the impact of acute and chronic LSD administration on anxiety-like behavior, on the cortical dendritic spines and on the activity of serotonin (5-HT) neurons originating in the dorsal raphe nucleus (DRN) in male mice exposed to chronic restraint stress. We found that while the acute intraperitoneal (i.p.) administration of LSD (5, 15 and 30 and 60 μg/kg) did not produce any anxiolytic or antidepressant effects in non-stressed mice, the dose of 30 µg/kg (daily for 7 days) prevented the stress-induced anxiety-like behavior and the stress-induced decrease of cortical spine densitiy. Interestingly, while LSD acutely decreased the firing activity of 5-HT neurons, repeated LSD increased their basal firing rate and restored the low 5-HT firing induced by stress. This effect was accompanied by a decreased inhibitory response of 5-HT neurons to microiontophoretic applications of the 5-HT<sub>1A</sub> agonist 8-OH-DPAT (8-hydroxy-N,N-dipropyl-2-aminotetralin). In conclusion, repeated LSD prevents the exacerbation of anxiety-like behavior following chronic stress exposure, but has no behavioral effects in non-stressed mice. These effects are paralleled by increased cortical spinogenesis and an enhancement of 5-HT neurotransmission which might be due to 5-HT<sub>1A</sub> receptors desensitization. Increased cortical spine density and enhancement of serotonergic neurotransmission may thus represent a candidate mechanism which mediate the therapeutic effects of serotonergic psychedelics on stress-induced anxiety.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Gregorio</LastName>
            <ForeName>Danilo</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neuroscience, Vita Salute San Raffaele University, 20132, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Inserra</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Enns</LastName>
            <ForeName>Justine P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Markopoulos</LastName>
            <ForeName>Athanasios</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pileggi</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>El Rahimy</LastName>
            <ForeName>Youssef</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez-Canul</LastName>
            <ForeName>Martha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Comai</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-5686-7194</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Neuroscience, Vita Salute San Raffaele University, 20132, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gobbi</LastName>
            <ForeName>Gabriella</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-4124-9825</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, McGill University and Research Institute of the McGill University Health Center, H3A1A1, Montreal, QC, Canada. gabriella.gobbi@mcgill.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>436986</GrantID>
            <Agency>CIHR</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neuropsychopharmacology</MedlineTA>
        <NlmUniqueID>8904907</NlmUniqueID>
        <ISSNLinking>0893-133X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>333DO1RDJY</RegistryNumber>
          <NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8NA5SWF92O</RegistryNumber>
          <NameOfSubstance UI="D008238">Lysergic Acid Diethylamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014151" MajorTopicYN="Y">Anti-Anxiety Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008238" MajorTopicYN="N">Lysergic Acid Diethylamide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>DDG is a consultant at Diamond Therapeutics Inc, Toronto, ON, Canada. GG and DDG are inventors of a pending patent regarding the use of LSD. DDG was a recipient of Fond Recherche Québec-Santé (FRQS) and a Canadian Institutes for Health Research (CIHR) postdoctoral fellowships. AI is a recipient of a CIHR, FRQS and a Quebec Autism Research Training Program (QART) postdoctoral fellowships. ML-C was a recipient of a Faculty of Medicine of McGill University/Ferring postdoctoral fellowship. The other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35301424</ArticleId>
        <ArticleId IdType="pmc">PMC9018770</ArticleId>
        <ArticleId IdType="doi">10.1038/s41386-022-01301-9</ArticleId>
        <ArticleId IdType="pii">10.1038/s41386-022-01301-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nutt D. Psychedelic drugs-a new era inpsychiatry? Dialogues Clin Neurosci. 2019;21:139–47. doi: 10.31887/DCNS.2019.21.2/dnutt.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31887/DCNS.2019.21.2/dnutt</ArticleId>
            <ArticleId IdType="pmc">PMC6787540</ArticleId>
            <ArticleId IdType="pubmed">31636488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharm Rev. 2021;73:202–77. doi: 10.1124/pharmrev.120.000056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pharmrev.120.000056</ArticleId>
            <ArticleId IdType="pubmed">33328244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24. doi: 10.1038/s41583-020-0367-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41583-020-0367-2</ArticleId>
            <ArticleId IdType="pubmed">32929261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638. doi: 10.1038/npp.2016.82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2016.82</ArticleId>
            <ArticleId IdType="pmc">PMC5026740</ArticleId>
            <ArticleId IdType="pubmed">27249781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller F, Lenz C, Dolder PC, Harder S, Schmid Y, Lang UE, et al.  Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry. 2017;7:e1084. doi: 10.1038/tp.2017.54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/tp.2017.54</ArticleId>
            <ArticleId IdType="pmc">PMC5416695</ArticleId>
            <ArticleId IdType="pubmed">28375205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535–45. doi: 10.1007/s00213-017-4733-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-017-4733-3</ArticleId>
            <ArticleId IdType="pmc">PMC5813062</ArticleId>
            <ArticleId IdType="pubmed">28918441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carhart-Harris RL, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R, et al.  The paradoxical psychological effects of lysergic acid diethylamide (LSD) Psychological Med. 2016;46:1379–90. doi: 10.1017/S0033291715002901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0033291715002901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29:57–68. doi: 10.1177/0269881114555249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881114555249</ArticleId>
            <ArticleId IdType="pubmed">25389218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al.  Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513. doi: 10.1097/NMD.0000000000000113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NMD.0000000000000113</ArticleId>
            <ArticleId IdType="pmc">PMC4086777</ArticleId>
            <ArticleId IdType="pubmed">24594678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. LSD therapy for persons suffering from major depression (LAD). ClinicalTrials.gov Identifier: NCT03866252; https://clinicaltrials.gov/ct2/show/NCT03866252. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, et al.  The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res. 2016;113:81–91. doi: 10.1016/j.phrs.2016.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2016.08.022</ArticleId>
            <ArticleId IdType="pubmed">27544651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci. 2016;17:1953. doi: 10.3390/ijms17111953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17111953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marona-Lewicka D, Chemel BR, Nichols DE. Dopamine D 4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology. 2009;203:265–77. doi: 10.1007/s00213-008-1238-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-008-1238-0</ArticleId>
            <ArticleId IdType="pubmed">18604600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology. 2014;83:1–8. doi: 10.1016/j.neuropharm.2014.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2014.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC4098645</ArticleId>
            <ArticleId IdType="pubmed">24704148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci. 2021;118:e2020705118.</Citation>
        </Reference>
        <Reference>
          <Citation>Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ, et al.  Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci. 2008;1148:86–94. doi: 10.1196/annals.1410.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1410.004</ArticleId>
            <ArticleId IdType="pubmed">19120094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishitani N, Nagayasu K, Asaoka N, Yamashiro M, Andoh C, Nagai Y, et al.  Manipulation of dorsal raphe serotonergic neurons modulates active coping to inescapable stress and anxiety-related behaviors in mice and rats. Neuropsychopharmacology. 2019;44:721–32. doi: 10.1038/s41386-018-0254-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41386-018-0254-y</ArticleId>
            <ArticleId IdType="pmc">PMC6372597</ArticleId>
            <ArticleId IdType="pubmed">30377380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambico FR, Nguyen N-T, Gobbi G. Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. Eur Neuropsychopharmacol. 2009;19:215–28. doi: 10.1016/j.euroneuro.2008.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2008.11.005</ArticleId>
            <ArticleId IdType="pubmed">19147333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109. doi: 10.1038/sj.npp.1301574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.npp.1301574</ArticleId>
            <ArticleId IdType="pubmed">17851537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, et al.  Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125–35. doi: 10.1038/mp.2012.90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2012.90</ArticleId>
            <ArticleId IdType="pmc">PMC4148304</ArticleId>
            <ArticleId IdType="pubmed">22776900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghajanian GK, Foote WE, Sheard MH. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science. 1968;161:706–08. doi: 10.1126/science.161.3842.706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.161.3842.706</ArticleId>
            <ArticleId IdType="pubmed">4874578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al.  Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci. 2021;118:e2020705118. doi: 10.1073/pnas.2020705118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.2020705118</ArticleId>
            <ArticleId IdType="pmc">PMC7865169</ArticleId>
            <ArticleId IdType="pubmed">33495318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borison RL, Havdala HS, Diamond BI. Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia? Life Sci. 1977;21:117–22. doi: 10.1016/0024-3205(77)90431-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0024-3205(77)90431-3</ArticleId>
            <ArticleId IdType="pubmed">560609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49. doi: 10.1038/nm.4050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4050</ArticleId>
            <ArticleId IdType="pmc">PMC5405628</ArticleId>
            <ArticleId IdType="pubmed">26937618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2012;13:22–37. doi: 10.1038/nrn3138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn3138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, et al.  Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870–74. doi: 10.1523/JNEUROSCI.1184-06.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1184-06.2006</ArticleId>
            <ArticleId IdType="pmc">PMC6674229</ArticleId>
            <ArticleId IdType="pubmed">16870732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al.  Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82. doi: 10.1016/j.celrep.2018.05.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.05.022</ArticleId>
            <ArticleId IdType="pmc">PMC6082376</ArticleId>
            <ArticleId IdType="pubmed">29898390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994;15:220–6. doi: 10.1016/0165-6147(94)90315-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-6147(94)90315-8</ArticleId>
            <ArticleId IdType="pubmed">7940983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19:378–83. doi: 10.1016/S0166-2236(96)10037-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-2236(96)10037-0</ArticleId>
            <ArticleId IdType="pubmed">8873352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aghajanian GK, Foote WE, Sheard MH. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Therap. 1970;171:178–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5459056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haigler HJ, Aghajanian GK. Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain. Eur J Pharmacol. 1973;21:53–60. doi: 10.1016/0014-2999(73)90206-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-2999(73)90206-9</ArticleId>
            <ArticleId IdType="pubmed">4709205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides. 2005;26:1383–93. doi: 10.1016/j.peptides.2005.03.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.peptides.2005.03.032</ArticleId>
            <ArticleId IdType="pubmed">16042978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambico FR, Cassano T, Dominguez-Lopez S, Katz N, Walker CD, Piomelli D, et al.  Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology. 2010;35:2083–100. doi: 10.1038/npp.2010.80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2010.80</ArticleId>
            <ArticleId IdType="pmc">PMC3055302</ArticleId>
            <ArticleId IdType="pubmed">20571484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG, Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur J Pharmacol. 2004;487:125–32. doi: 10.1016/j.ejphar.2004.01.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2004.01.031</ArticleId>
            <ArticleId IdType="pubmed">15033384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A. 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology. 2004;46:52–62. doi: 10.1016/j.neuropharm.2003.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2003.08.007</ArticleId>
            <ArticleId IdType="pubmed">14654097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikiforuk A, Kos T, Fijał K, Hołuj M, Rafa D, Popik P. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013;8:e66695. doi: 10.1371/journal.pone.0066695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0066695</ArticleId>
            <ArticleId IdType="pmc">PMC3679060</ArticleId>
            <ArticleId IdType="pubmed">23776692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guscott M, Egan E, Cook G, Stanton J, Beer M, Rosahl T, et al.  The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44:1031–37. doi: 10.1016/S0028-3908(03)00117-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0028-3908(03)00117-5</ArticleId>
            <ArticleId IdType="pubmed">12763096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markopoulos A, Inserra A, De Gregorio D, Gobbi G. Evaluating the potential use of serotonergic psychedelics in autism spectrum disorder. Front Pharmacol. 2022;12:749068. doi: 10.3389/fphar.2021.749068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.749068</ArticleId>
            <ArticleId IdType="pmc">PMC8846292</ArticleId>
            <ArticleId IdType="pubmed">35177979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therap Adv Psychopharmacol. 2016;6:193–213. doi: 10.1177/2045125316638008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2045125316638008</ArticleId>
            <ArticleId IdType="pmc">PMC4910400</ArticleId>
            <ArticleId IdType="pubmed">27354908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–78. doi: 10.1001/archgenpsychiatry.2010.116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.116</ArticleId>
            <ArticleId IdType="pubmed">20819978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97. doi: 10.1177/0269881116675513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881116675513</ArticleId>
            <ArticleId IdType="pmc">PMC5367557</ArticleId>
            <ArticleId IdType="pubmed">27909165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci. 2020;11:864–71. doi: 10.1021/acschemneuro.9b00493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschemneuro.9b00493</ArticleId>
            <ArticleId IdType="pubmed">32133835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchborn T, Schröder H, Höllt V, Grecksch G. Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J Psychopharmacol. 2014;28:545–52. doi: 10.1177/0269881114531666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881114531666</ArticleId>
            <ArticleId IdType="pubmed">24785760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vesuna S, Kauvar IV, Richman E, Gore F, Oskotsky T, Sava-Segal C, et al.  Deep posteromedial cortical rhythm in dissociation. Nature. 2020;586:87–94. doi: 10.1038/s41586-020-2731-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2731-9</ArticleId>
            <ArticleId IdType="pmc">PMC7553818</ArticleId>
            <ArticleId IdType="pubmed">32939091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossman L, Utterback E, Stewart A, Gaikwad S, Chung KM, Suciu C, et al.  Characterization of behavioral and endocrine effects of LSD on zebrafish. Behavioural Brain Res. 2010;214:277–84. doi: 10.1016/j.bbr.2010.05.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2010.05.039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N, N-Dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261–70. doi: 10.1021/acschemneuro.8b00692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschemneuro.8b00692</ArticleId>
            <ArticleId IdType="pmc">PMC6639775</ArticleId>
            <ArticleId IdType="pubmed">30829033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jefsen O, Højgaard K, Christiansen SL, Elfving B, Nutt DJ, Wegener G, et al.  Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta Neuropsychiatrica. 2019;31:213–19. doi: 10.1017/neu.2019.15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/neu.2019.15</ArticleId>
            <ArticleId IdType="pubmed">31106729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoudi E, Faizi M, Hajiaghaee R, Razmi A. Alteration of depressive-like behaviors by psilocybe cubensis alkaloid extract in mice: the role of glutamate pathway. Res J Pharmacogn. 2018;5:17–24.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong M-L, Inserra A, Lewis M, Mastronardi CA, Leong L, Choo J, et al.  Inflammasome signaling affects anxiety-and depressive-like behavior and gut microbiome composition. Mol Psychiatry. 2016;21:797–805. doi: 10.1038/mp.2016.46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2016.46</ArticleId>
            <ArticleId IdType="pmc">PMC4879188</ArticleId>
            <ArticleId IdType="pubmed">27090302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strekalova T, Couch Y, Kholod N, Boyks M, Malin D, Leprince P, et al.  Update in the methodology of the chronic stress paradigm: internal control matters. Behav Brain Funct. 2011;7:1–18. doi: 10.1186/1744-9081-7-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1744-9081-7-9</ArticleId>
            <ArticleId IdType="pmc">PMC3023691</ArticleId>
            <ArticleId IdType="pubmed">21205317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C, Kunugi H. Chronic restraint stress causes anxiety-and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39:112–19. doi: 10.1016/j.pnpbp.2012.05.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pnpbp.2012.05.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Buisman-Pijlman FTA, Nunez-Salces M, Christie S, Frisby CL, Inserra A, et al.  Chronic stress induces hypersensitivity of murine gastric vagal afferents. Neurogastroenterol Motil. 2019;31:e13669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31241809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambico FR, Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis? Curr Top Behav Neurosci. 2013;15:243–91. doi: 10.1007/7854_2012_234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/7854_2012_234</ArticleId>
            <ArticleId IdType="pubmed">23271325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64. doi: 10.1126/science.1190287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1190287</ArticleId>
            <ArticleId IdType="pmc">PMC3116441</ArticleId>
            <ArticleId IdType="pubmed">20724638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.</Citation>
        </Reference>
        <Reference>
          <Citation>Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al.  N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020;10:331. doi: 10.1038/s41398-020-01011-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41398-020-01011-0</ArticleId>
            <ArticleId IdType="pmc">PMC7522265</ArticleId>
            <ArticleId IdType="pubmed">32989216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inserra A, De Gregorio D, Rezai T, Lopez-Canul MG, Comai S, Gobbi G. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. J Psychopharmacol. 2021;35:469–82. doi: 10.1177/0269881121991569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269881121991569</ArticleId>
            <ArticleId IdType="pmc">PMC8058830</ArticleId>
            <ArticleId IdType="pubmed">33645311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NRPW Hutten, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, et al.  Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Trans Sci. 2021;4:461–66. doi: 10.1021/acsptsci.0c00099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsptsci.0c00099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida RND, Galvão ACDM, da Silva FS, Silva EADS, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 2019;10:1234.</Citation>
        </Reference>
        <Reference>
          <Citation>Cini FA, Ornelas I, Marcos E, Goto-Silva L, Nascimento J, Ruschi S, et al. d-Lysergic acid diethylamide has major potential as a cognitive enhancer. bioRxiv. 2019, https://www.biorxiv.org/content/10.1101/866814v1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/866814v1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willner P. Antidepressants and serotonergic neurotransmission: an integrative review. Psychopharmacology. 1985;85:387–404. doi: 10.1007/BF00429653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00429653</ArticleId>
            <ArticleId IdType="pubmed">2410942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade R, Huereca D, Lyons JG, Andrade EM, McGregor KM. 5-HT1A receptor-mediated autoinhibition and the control of serotonergic cell firing. ACS Chem Neurosci. 2015;6:1110–15. doi: 10.1021/acschemneuro.5b00034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschemneuro.5b00034</ArticleId>
            <ArticleId IdType="pmc">PMC4849862</ArticleId>
            <ArticleId IdType="pubmed">25913021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anyan J, Amir S. Too depressed to swim or too afraid to stop? A reinterpretation of the forced swim test as a measure of anxiety-like behavior. Neuropsychopharmacology. 2018;43:931–33. doi: 10.1038/npp.2017.260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2017.260</ArticleId>
            <ArticleId IdType="pmc">PMC5854810</ArticleId>
            <ArticleId IdType="pubmed">29210364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molendijk ML, de Kloet ER. Coping with the forced swim stressor: current state-of-the-art. Behavioural brain Res. 2019;364:1–10. doi: 10.1016/j.bbr.2019.02.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbr.2019.02.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Commons KG, Cholanians AB, Babb JA, Ehlinger DG. The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem Neurosci. 2017;8:955–60. doi: 10.1021/acschemneuro.7b00042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschemneuro.7b00042</ArticleId>
            <ArticleId IdType="pmc">PMC5518600</ArticleId>
            <ArticleId IdType="pubmed">28287253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Der-Avakian A, Mazei-Robison MS, Kesby JP, Nestler EJ, Markou A. Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response. Biol Psychiatry. 2014;76:542–49. doi: 10.1016/j.biopsych.2014.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopsych.2014.01.013</ArticleId>
            <ArticleId IdType="pmc">PMC4117827</ArticleId>
            <ArticleId IdType="pubmed">24576687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreira PS, Almeida PR, Leite-Almeida H, Sousa N, Costa P. Impact of chronic stress protocols in learning and memory in rodents: systematic review and meta-analysis. PLoS One. 2016;11:e0163245. doi: 10.1371/journal.pone.0163245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0163245</ArticleId>
            <ArticleId IdType="pmc">PMC5035061</ArticleId>
            <ArticleId IdType="pubmed">27662580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patki G, Solanki N, Atrooz F, Allam F, Salim S. Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress. Brain Res. 2013;1539:73–86. doi: 10.1016/j.brainres.2013.09.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2013.09.033</ArticleId>
            <ArticleId IdType="pmc">PMC4316676</ArticleId>
            <ArticleId IdType="pubmed">24096214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meehan SM, Schechter MD. LSD produces conditioned place preference in male but not female fawn hooded rats. Pharmacol Biochem Behav. 1998;59:105–08. doi: 10.1016/S0091-3057(97)00391-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0091-3057(97)00391-2</ArticleId>
            <ArticleId IdType="pubmed">9443543</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
